affimed.com rapport :   Visitez le site

Données techniques du affimed.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte affimed.com.Actuellement, hébergé dans United States et son fournisseur de services est 1&1 Internet AG .

the related websites

domaine	Titre
affimed.com	affimed

boursier.com hotel-chatnoir-paris.com lepoint.fr cat.inist.fr oecd.org 

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

 about about business strategy management board of directors investors careers rock ® platform tandab® antibodies tandab® technology tandab® recruit tandab® biblock tandab® prolong technology development products products afm13 afm11 discovery portfolio investors & media media room press releases events & conferences scientific publications careers contact our mission breakthrough cancer therapies: directing the immune system to eliminate tumor cells. is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. its product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. the most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or nk-cells, and t-cells. ’s proprietary, next-generation bispecific antibodies, termed tandabs® because of their tandem antibody structure, are designed to direct and establish a bridge between either nk-cells or t-cells and cancer cells. ’s tandabs have the ability to bring nk-cells or t-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent architecture (which provides for four binding domains), the tandabs bind to their targets with high affinity and have half-lives that allow intravenous administration. believes, based on the tandabs mechanism of action and the preclinical and clinical data it has generated to date, that its product candidates may ultimately improve response rates, clinical outcomes and survival in cancer patients and could eventually become a cornerstone of modern targeted oncology care. has focused its research and development efforts on moving novel immune cell engager based therapies through clinical development. because tandabs bind with receptors that are known to be present on a number of types of cancer cells, each of ’s tandab product candidates could be developed for the treatment of several different cancers. intends to initially develop its two clinical stage product candidates in orphan or high-medical need indications, including development as a salvage therapy for patients who have relapsed after, or are refractory to, that is who do not respond to treatment with, standard therapies. generates its pipeline of product candidates from three proprietary next-generation antibody-engineering technologies: nk-cell tandabs – tetravalent, bifunctional proteins that recognize a specific biologic target and, utilizing their second functionality, bind with high affinity to cd16a on nk cells and thereby direct the nk-cells to eliminate the target cell. t-cell tandabs – tetravalent, bifunctional proteins that recognize a specific biologic target and utilizing their second functionality, bind with high affinity to cd3 on t-cells and thereby direct the t-cell to eliminate the target cell. trispecific abs for dual targeting of tumor cells – trifunctional structures that can be designed to target two different targets/epitopes on the tumor cell and with the third functionality bind with high affinity to either t-cells or nk-cells. pipeline impressum disclaimer data privacy

Analyse PopURL pour affimed.com

http://www.affimed.com/products.php
http://www.affimed.com/data-privacy.php
http://www.affimed.com/careers.php
http://www.affimed.com/impressum.php
http://www.affimed.com/index.php
http://www.affimed.com/about.php
http://www.affimed.com/investor-relations.php
http://www.affimed.com/disclaimer.php
http://www.affimed.com/rock-platform.php
http://www.affimed.com/contact.php

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: AFFIMED.COM
Registry Domain ID: 21341246_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.1and1.com
Registrar URL: http://registrar.1and1.info
Updated Date: 2017-03-05T08:17:21Z
Creation Date: 2000-03-04T11:49:08Z
Registry Expiry Date: 2018-03-04T11:49:08Z
Registrar: 1&1 Internet SE
Registrar IANA ID: 83
Registrar Abuse Contact Email: abuse@1and1.com
Registrar Abuse Contact Phone: +1.6105601459
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS15.SCHLUND.DE
Name Server: NS16.SCHLUND.DE
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-19T07:43:40Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR 1&1 Internet SE

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =affimed.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME affimed.com

  CHANGED 2017-03-05

  CREATED 2000-03-04

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS15.SCHLUND.DE 217.160.80.139

  NS16.SCHLUND.DE 217.160.81.139

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.